USPTO serial 87146623
REXADEV
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- AGOSTO, GISELLE MARIE
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with REXADEV?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Thousand Oaks, CA
Thousand Oaks, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Timothy J. Gaul
Timothy J. Gaul Amgen Inc.One Amgen Center DriveTrademark Operations-MS-28-5AThousand Oaks, CA 91320-1799Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | pharmaceutical preparations, biosimilars and pharmaceutical substances used for the treatment of bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, blood cells, blood vessel, and blood diseases and disorders; pharmaceutical preparations, biosimilars and pharmaceutical substances for the treatment of autoimmune, immune system, inflammatory, inflammatory bowel, gastrointestinal, genitourinary, musculoskeletal, dermatological, pulmonary, respiratory, oncological, hepatological, lymphomas, leukemias, ophthalmic, transplant rejection, cardiovascular, endocrine, neurological, sleep, muscular, and psychiatric diseases and disorders; pharmaceutical preparations and biosimilars, namely, pharmaceutical preparations and pharmaceutical substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, polymyalgia rheumatic, spondyloarthropathies, acute disc prolapse, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Intestinal Behçet's Disease, chronic pouchitis, small bowel lesions, Hermansky-Pudlak syndrome, autoimmune pancreatitis, multiple myeloma, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, chronic inflammatory demyelinating polyneuropathy, autoimmune anemia, autoimmune hemolytic anemia, pure red cell aplasia, idiopathic thrombocytopenic purpura, Evans syndrome, type 1 diabetes mellitus, Sjogren's syndrome, encephalitis, IgG4-related disease, Devic's disease, myositis, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, palmoplantar psoriasis, hidradenitis suppurativa, bullous skin disorder, pemphigus, pemphigoid, kawasaki disease, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, age-related macular degeneration, refractory diabetic macular edema, uveitis, childhood uveitis, uveitic macular edema, choroidal neovascularization, Graves' ophthalmopathy, pyoderma gangrenosum, giant cell arteritis, Netherton syndrome, anaplastic thyroid cancer, breast cancer, ovarian cancer, cervical cancer, gastric cancer, colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, head and neck cancer, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, lymphocyte predominant subtype of Hodgkin's Lymphoma, vasculitis, granulomatosis with polyangiitis, microscopic polyangiitis, graft-versus-host disease, graft-versus-host disease following allogenic hematopoietic stem cell transplantation, graft-versus-host disease following keratoprosthesis, kidney transplant, asthma, chronic fatigue syndrome, major depression, and bipolar depression | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 8, 2020 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 7, 2020 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Nov 23, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 22, 2019 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Nov 22, 2019 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Nov 20, 2019 | EXT5 | SOU EXTENSION 5 FILED | — |
| Nov 20, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 28, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 24, 2019 | EX4G | SOU EXTENSION 4 GRANTED | — |
| May 24, 2019 | EXT4 | SOU EXTENSION 4 FILED | — |
| May 24, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 7, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 7, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 24, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 22, 2019 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jan 22, 2019 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jan 22, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 14, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 12, 2018 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jul 12, 2018 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jul 12, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 27, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 25, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 25, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 25, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 1, 2017 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 6, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 6, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 17, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 26, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 25, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 24, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 24, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 24, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 31, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 31, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 31, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 28, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 25, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 25, 2016 | NWAP | NEW APPLICATION ENTERED | — |